M&A In Global Healthcare & Life Sciences – 2023

by Jan 31, 2024Analysis, M&A

M&A’s are resurging as deal values returned higher in the fourth quarter, though on fewer deals. Equipped with substantial resources, large pharmaceutical companies are inclined to pursue higher-value deals. Pfizer’s acquisition of cancer specialist Seagen is a prime example. This transaction is the largest in biopharma since 2019, valued at $43 billion. Bristol Myers Squibb aimed to acquire Karuna for $14.0 billion, featuring the innovative antipsychotic KarXT, with a 53% one-day premium. Merck’s successful acquisition of Prometheus Biosciences for $10.8 billion offered stakeholders $200 per share in cash, a 75% one-day premium.

CVS Health acquired Oak Street Health for $10.6 billion, with Oak Street receiving $39 per share in cash and a 16% one-day premium. AbbVie acquired ImmunoGen for $10.1 billion, gaining Elahere, an approved ADC for Ovarian Cancer. Lastly, AbbVie acquired Cerevel Therapeutics for $8.7 billion. The trend highlights opportunities for larger companies to acquire niche-focused smaller biotechs, enhancing innovation and expanding drug pipelines.


M&A In Biopharma, Platform, Medtech, And Diagnostics

Biopharma, Platform, Medtech, and Diagnostics M&A

During 2023, 254 deals were announced, a decline from the previous year’s 285. Despite the decrease in deal volume, the total deal value increased to $209.8 billion, up from $143.6 billion in 2022. Remarkably, a substantial portion of the 2023 M&A, $196.3 billion, involved cash transactions with contingents.



M&A By Subsector

Healthcare and Life Sciences M&A by Subsector

In 2023, 118 transactions made $158.1 billion, surpassing the previous year’s $85.4 billion across 104 deals. The Medtech, device, digital Tx, and wearables also witnessed a rise in deal value, reaching $14.2 billion in 47 deals, compared to $28.3 billion in 51 deals in 2022. Diagnostics, sequencing, omics, and tools demonstrated resilience with 50 deals totaling $13.5 billion in 2023. In contrast, Manufacturing tech and others increased in deal value, rising to $24.0 billion across 39 deals in 2023 from $21.0 billion in 59 deals in 2022.


M&A In Biopharma Therapeutics For 2023

Biopharma Therapeutics and Platform M&A

In 2023, M&A saw 101 transactions, surpassing 81 in 2022. The total M&A value in 2023 soared to $154.2 billion, a substantial increase from $78.9 billion in 2022. The cash component of these transactions reached $144.8 billion in 2023.



M&A By Clinical Development Milestones

Biopharma M&A by Target Company Stage – 2023

The platform stage witnessed 5 transactions totaling $0.26 billion. Preclinical had 17 deals, contributing to a total value of $2.48 billion, of which $1.04 billion was in cash without contingents. Phase-I companies contributed 15 deals, generating $4.42 billion with $3.89 billion in cash. Phase-II saw 23 amounting to $22.82 billion, primarily in cash at $18.55 billion. The Phase-III saw 15 deals making $49.07 billion, predominantly in cash ($48.20 billion). Approved-stage engaged in 16 transactions, reflecting the highest total value at $74.43 billion, with $72.99 billion in cash.



M&A Across Top Modalities

M&A – Top Biopharma Modalities – 2023

Biologics (antibodies, DNA, RNA, and proteins) emerged with 35 deals valued at $90.0 billion; these cash components were $86.6 billion. Small Molecule attracted 39 deals, accumulating $54.4 billion, of which $50.0 billion comprised cash transactions. Gene Therapy and vectors, although fewer in number, with 6 deals, generated $1.9 billion in total with $1.4 billion in cash.



M&A In The Top Therapy Areas For 2023

M&A – Top Therapy Areas – 2023

Cancer therapies consistently rank highest, with 66 deals valued at $79.7 billion. Without contingents, the cash component reached $76.0 billion. Neurologic garnered 33 deals totaling $35.1 billion with a cash outlay of $33.3 billion. Autoimmune recorded 10 deals, contributing $21.4 billion, with $21.1 billion in cash.


Top M&A Deals In Global Healthcare & Life Sciences

Pfizer’s Acquisition of Seagen (December 2023)

  • Overview: Pfizer acquires Seagen, known for assets in cancer treatment.
  • Key Assets: Adcetris, Padcev, Tivdak, and more.
  • Transaction Details: $229 per share in cash, 32.7% premium, $43 billion total.

AbbVie’s Acquisition of Cerevel Therapeutics (December 2023)

  • Overview: AbbVie acquires Cerevel for assets in neurological treatments.
  • Key Assets: Emraclidine, Tavapadon, CVL-354, and Darigabat.
  • Transaction Details: $45.00 per share in cash, 22% premium, $8.7 billion total.

AbbVie’s Acquisition of Immunogen (November 2023)

  • Overview: AbbVie acquires ImmunoGen for Elahere, an ADC for Ovarian Cancer.
  • Key Assets: Elahere, pivekimab sunirine, IMGC-936, and IMGN-151.
  • Transaction Details: $31.26 per share in cash, 95% premium, $10.1 billion total.

Merck’s Acquisition of Prometheus Biosciences (June 2023)

  • Overview: Merck acquires Prometheus with a focus on immune-mediated diseases.
  • Key Assets: PRA-023, PRA-052, PR-1100, and more.
  • Transaction Details: $200 per share in cash, 75% premium, $10.8 billion total.

CVS Health’s Acquisition of Oak Street Health (May 2023)

  • Overview: CVS Health acquires Oak Street for primary care services to older adults.
  • Transaction Details: $39 per share in cash, 16% premium, $10.6 billion total.

BMS Acquisition of Karuna (Anticipated Closing First Half Of 2024)

  • Overview: BMS to acquire Karuna focusing on psychiatric treatments.
  • Key Asset: KarXT for schizophrenia and Alzheimer’s psychosis.
  • Transaction Details: $330.00 per share, 53% premium, $14 Billion total



Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Venture Activity In Global Healthcare & Life Sciences – 2023

Venture Activity In Global Healthcare & Life Sciences – 2023

An increase in down rounds in 2023 indicates a reassessment of valuations in VC. Challenges are expected to persist in the sector through the H1 of 2024, grappling with repercussions from previous excesses and a challenging fundraising environment. The initiation of a...